The drug is now in Phase 2 clinical trials in patients with Alzheimer’s and Fragile X syndrome
A new drug discovered through a research collaboration between the University at Buffalo and Tetra Therapeutics may protect against memory loss, nerve damage and other symptoms of Alzheimer’s disease.
Preclinical research found that the drug — called BPN14770 — deters the effects of amyloid beta, a hallmark protein of Alzheimer’s that is toxic to nerve cells.
Recent studies find Alzheimer’s may develop without dementia in nearly 25% of healthy 80-year-old patients, suggesting the body may turn to compensatory mechanisms to maintain the nervous system.
BPN14770, under development by Tetra Therapeutics, could help activate these mechanisms that support nerve health and prevent dementia, even with the progression of Alzheimer’s.
Its benefits could also translate to Fragile X syndrome, developmental disabilities and schizophrenia, researchers say.
“Such observations imply that Alzheimer’s pathology can be tolerated by the brain to some extent due to compensatory mechanisms operating at the cellular and synaptic levels,” said Ying Xu, MD, PhD, co-lead investigator and research associate professor in the UB School of Pharmacy and Pharmaceutical Sciences.
“Our new research suggests that BPN14770 may be capable of activating multiple biological mechanisms that protect the brain from memory deficits, neuronal damage and biochemical impairments.”
The study, published on Sept. 5 in The Journal of Pharmacology and Experimental Therapeutics, was also led by James M. O’Donnell, PhD, dean and professor of the UB School of Pharmacy and Pharmaceutical Sciences. Mark E. Gurney, PhD, chairman and chief executive officer of Tetra Therapeutics, based in Grand Rapids, Michigan, collaborated on the research.
Guarding memory against toxic proteins
The research, conducted in mice, discovered that BPN14770 inhibits the activity of phosphodiesterase?4D (PDE4D), an enzyme that plays a key role in memory formation, learning, neuroinflammation and traumatic brain injury.
PDE4D lowers cyclic adenosine monophosphate (cAMP) — a messenger molecule that signals physiological changes such as cell division, change, migration and death — in the body, leading to physical alterations in the brain.
cAMP has numerous beneficial functions, including improved memory. By inhibiting PDE4D, BPN14770 increases cAMP signaling in the brain, which ultimately protects against the toxic effects of amyloid beta.
“The role of PDE4D in modulating brain pathways involved in memory formation and cognition, and the ability of our PDE4D inhibitor to selectively enhance this process, has been well studied,” said Gurney. “We are very excited by our colleagues’ findings, which now suggest a second protective mechanism of action for BPN14770 against the progressive neurological damage associated with Alzheimer’s disease.”
“Developing effective drugs for memory deficits associated with Alzheimer’s disease has been challenging,” said O’Donnell. “BPN14770 works by a novel mechanism to increase cyclic AMP signaling in the brain, which has been shown to improve memory. The collaborative project has led to clinical trials that will begin to test its effectiveness.”
Tetra Therapeutics is conducting Phase 2 clinical trials of BPN14770 in patients with early Alzheimer’s and adults with Fragile X syndrome, a genetic disorder that causes intellectual and developmental disabilities.
Results of previous Phase 1 studies in healthy elderly volunteers suggest the drug benefits working, or immediate, memory. Animal studies found that BPN14770 has the potential to promote the maturation of connections between neurons, which are impaired in patients with Fragile X syndrome, as well as protect these connections, which are lost in patients with Alzheimer’s.
“There has been enormous interest in our ongoing Phase 2 trial of BPN14770 in 255 patients with early Alzheimer’s, and we are hopeful this study will show an impact of PDE4D modulation in this disease. Topline results are expected mid-2020,” said Gurney.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Famed Restaurateur and Lifestyle Guru B. Smith Dies of Alzheimer's Disease at Age 70on February 23, 2020 at 11:07 pm
B. Smith has died following a years-long battle with Alzheimer’s disease. She was 70. “It is with great sadness that my daughter Dana and I announce the passing of my wife, Barbara Elaine Smith,” her ...
- B. Smith, Lifestyle Guru, Restaurateur And Former Model, Dies From Alzheimer’s Diseaseon February 23, 2020 at 4:27 pm
B. Smith, the groundbreaking lifestyle guru, restaurateur, author and former model, died on Saturday (Feb. 22) from early on-set Alzheimer’s disease. She was 70. Smith’s husband, Dan Gasby, announced ...
- B. Smith, Lifestyle Guru, Restauranteur And Former Model, Dies From Alzheimer’s Diseaseon February 23, 2020 at 3:57 pm
Viola Davis, Ava DuVernay and more honor the legendary entrepreneur. B. Smith, the groundbreaking lifestyle guru, restauranteur, author and former model, died on Saturday (Feb. 22) from early on-set ...
- Model, restaurateur B. Smith dies at 70 during battle with early onset Alzheimer'son February 23, 2020 at 12:38 pm
B. Smith, the model turned lifestyle guru and restaurateur, has died at 70 years old during her battle with early onset Alzheimer's, her husband, Dan Gasby, announced on Sunday. Barbara Elaine Smith ...
- B. Smith's husband criticized for having girlfriend while she battles Alzheimer'son February 23, 2020 at 12:08 pm
Dan Gasby has fired back at critics upset that he has a girlfriend while caring for his ailing wife of 26 years.
- B. Smith, model-turned-TV host and lifestyle guru, dies at 70 after Alzheimer's battleon February 23, 2020 at 9:47 am
B. Smith, one of the country's first high-profile black models who went on to become an author, restaurateur and lifestyle maven, has died after a seven-year battle with Alzheimer's disease. She was ...
- B. Smith, a model turned lifestyle guru and restaurant owner, dead at 70 after battling early onset Alzheimer’s diseaseon February 23, 2020 at 9:02 am
NEW YORK — B. Smith, a model turned lifestyle guru and restaurant owner, dead at 70 after battling early onset Alzheimer’s disease. Copyright 2020 The Associated Press. All rights reserved. This ...
- SUNY Proposes Initiative to Map Genes of 1 Million People With or At-Risk of Alzheimer’son February 21, 2020 at 9:07 pm
Researchers would aim to map the genes of one million people living with or at-risk of Alzheimer's disease over five years through a proposed initiative at the State University of New York. Gov.
- Alzheimer's Society 'paid out £750,000' to staff amid bullying claimson February 21, 2020 at 8:00 am
Exclusive: Charity could be accused of using NDAs to silence staff, whistleblower alleges ...
- NY project would map genes of 1 million to fight Alzheimer'son February 21, 2020 at 6:00 am
ALBANY, N.Y. (AP) - Researchers would aim to map the genes of one million people living with or at-risk of Alzheimer's disease over five years through a proposed initiative at the State University of ...
via Bing News